Table 1.
Table of patient characteristics in apixaban, dabigatran, VKA and rivaroxaban groups.
| VKA (10,844) | Rivaroxaban (n = 7,572) | Apixaban (n = 1,066) | Dabigatran (96) | |
|---|---|---|---|---|
| Patient characteristic | ||||
| Median age (IQR+) | 66 [53–76] | 66 [52–76] | 69 [55–79] | 71 [59–80] |
| Males (%) | 5,775 (53.3) | 4,109 (54.3) | 532 (49.9) | 45 (46.9) |
| Index event (%) | ||||
| PE | 4,130 (38.1) | 3,035 (40.1) | 595 (55.8) | 46 (47.9) |
| DVT | 6,714 (61.9) | 4,537 (59.9) | 471 (44.2) | 50 (52.1) |
| Comorbidities (%) | ||||
| Previous venous thromboembolism | 1,973 (18.2) | 911 (12.0) | 101 (9.5) | 10 (10.4) |
| Previous bleeding | 1,099 (10.1) | 691 (9.1) | 111 (10.4) | 9 (9.4) |
| Stroke | 759 (7.0) | 420 (5.5) | 88 (8.3) | 8 (8.3) |
| Acute myocardial infarction | 426 (3.9) | 205 (2.7) | 51 (4.8) | <3 |
| Ischemic heart disease | 1,249 (11.5) | 676 (8.9) | 148 (13.9) | 6 (6.2) |
| Peripheral vascular disease | 307 (2.8) | 148 (2.0) | 23 (2.2) | 3 (3.1) |
| Vascular disease | 685 (6.3) | 342 (4.5) | 69 (6.5) | 5 (5.2) |
| Chronic heart failure | 509 (4.7) | 332 (4.4) | 49 (4.6) | 4 (4.2) |
| Chronic kidney disease | 550 (5.1) | 188 (2.5) | 38 (3.6) | 0 (0.0) |
| Liver disease | 224 (2.1) | 112 (1.5) | 21 (2.0) | <3 |
| Hypertension | 2,796 (25.8) | 1,723 (22.8) | 286 (26.8) | 16 (16.7) |
| Diabetes mellitus | 839 (7.7) | 542 (7.2) | 88 (8.3) | 7 (7.3) |
| Cancer | 1,499 (13.8) | 844 (11.1) | 134 (12.6) | 15 (15.6) |
| COPD | 1077 (9.9) | 618 (8.2) | 123 (11.5) | 16 (16.7) |
| Thrombophilia § | 211 (1.9) | 71 (0.9) | 4 (0.4) | 0 (0.0) |
| Alloplastic surgery | 205 (1.9) | 169 (2.2) | 23 (2.2) | <3 |
| Concomitant medication (%) | ||||
| ADP-receptor blockers | 518 (4.8) | 366 (4.8) | 84 (7.9) | 10 (10.4) |
| Aspirin | 1,814 (16.7) | 1,016 (13.4) | 167 (15.7) | 10 (10.4) |
| Diuretics | 2,436 (22.5) | 1,509 (19.9) | 250 (23.5) | 18 (18.8) |
| Beta-blockers | 1,649 (15.2) | 969 (12.8) | 169 (15.9) | 8 (8.3) |
| Calcium channel blockers | 1,701 (15.7) | 1,023 (13.5) | 177 (16.6) | 10 (10.4) |
| Renin-angiotensin system blockers | 3,055 (28.2) | 1,939 (25.6) | 310 (29.1) | 21 (21.9) |
| Loop diuretics | 1,417 (13.1) | 785 (10.4) | 140 (13.1) | 16 (16.7) |
| Ulcer medication | 2,555 (23.6) | 1,625 (21.5) | 284 (26.6) | 24 (25.0) |
| Lipid modifying agents | 2,188 (20.2) | 1,420 (18.8) | 232 (21.8) | 14 (14.6) |
| Hormone replacement therapy | 601 (5.5) | 448 (5.9) | 68 (6.4) | 4 (4.2) |
| Oral contraceptives | 547 (5.0) | 367 (4.8) | 41 (3.8) | <3 |
| Non steroidal anti- inflammatory drugs | 2,041 (18.8) | 1,437 (19.0) | 209 (19.6) | 17 (17.7) |
+IQR = Interquartile Range. §Thrombophilia (factor v Leiden, prothrombin mutation, protein C, S, and antithrombin deficiency, antiphospholid syndrome and cardiolipin syndrome). PE: Pulmonary embolism. DVT: Deep venous thromboembolism. COPD: Chronic obstructive pulmonary disease.